Ibio Limited

Phung Tu Gip

Mohan Srinivasan

Matthew Paul Greving

Bing Li

Angeles Estelles

Kevin Eduard Hauser

Jordan R Willis

Cody A Moore

Alex T Taguchi

Matt Lundberg

Christian Barrett

Andrew Morin

Provided herein engineered polypeptides that comprise a combination of spatially-associated topological constraints, wherein at least one constraint is derived from a CD25 reference target, and methods of selecting said engineered polypeptides. Further provided are methods of using the engineered polypeptides, including as positive and/or negative selection molecules in methods of screening a library of binding molecules such as antibodies. Further provided herein are CD25 antibodies selected using these engineered polypeptides.

Engineered CD25 polypeptides and uses thereof

Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.

CD25 antibodies

Growing community of inventors

San Francisco, CA, United States of America

Phung Tu Gip